'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study

(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…